Docetaxel Injection, Solution
Product Images NDC 67457-532

14 FDA label images from Mylan Institutional Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 67457-532). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Docetaxel Structrual Formula (Image 14)

Docetaxel Structrual Formula (Image 14)
Chemical structure of docetaxel anhydrous, the active ingredient in Docetaxel injection solution 10 mg/mL by Mylan Institutional LLC.*
FDA Label Image

Figure 1: Tax316 Disease Free Survival K-m Curve (Image 04)

Figure 1: Tax316 Disease Free Survival K-m Curve (Image 04)
A line graph showing Disease-Free Survival (DFS) Probability over time in months. Two curves are displayed: one solid line representing TAC and one dotted line representing FAC, with DFS probability on the vertical axis and Disease-Free Survival Time (months) on the horizontal axis.*
FDA Label Image

Figure 2: Tax316 Overall Survival K-m Curve (Image 05)

Figure 2: Tax316 Overall Survival K-m Curve (Image 05)
A survival probability curve chart plotting survival probability (%) on the vertical axis against survival time in months on the horizontal axis. Two lines compare treatment groups labeled TAC (solid line) and FAC (dotted line) over a period of 0 to 66 months.*
FDA Label Image

Figure 3: Tax317 Survival K-m Curves (Docetaxel 75 mg/m2 vs. Best Supportive Care)

Figure 3: Tax317 Survival K-m Curves (Docetaxel 75 mg/m2 vs. Best Supportive Care)
A Kaplan-Meier survival plot comparing overall survival probabilities over time in months between two groups labeled T75 and BSC. The graph shows cumulative probability on the y-axis and survival time on the x-axis, with a statistical significance indicator (Log.rank p = 0.010).*
FDA Label Image

Figure 4: Tax320 Survival K-m Curves (Docetaxel 75 mg/m2 vs. Vinorelbine or Ifosfamide Control)

Figure 4: Tax320 Survival K-m Curves (Docetaxel 75 mg/m2 vs. Vinorelbine or Ifosfamide Control)
A Kaplan-Meier survival curve graph showing cumulative probability over survival time in months. The chart compares overall survival between two groups labeled T75 and V/I, with survival probability on the vertical axis and time in months on the horizontal axis. A log-rank p-value of 0.13 is noted, indicating a statistical comparison between the groups.*
FDA Label Image

Figure 5: Tax327 Survival K-m Curves (Image 08)

Figure 5: Tax327 Survival K-m Curves (Image 08)
A survival probability curve chart depicting survival time in months on the x-axis and survival probability on the y-axis. Two lines are shown, one solid labeled T75 q3w and one dashed labeled M q3w, illustrating comparative survival trends over approximately 30 months.*
FDA Label Image

Figure 6: Gastric Cancer Study (tax325) Time To Progression K-m Curve (Image 09)

Figure 6: Gastric Cancer Study (tax325) Time To Progression K-m Curve (Image 09)
A Kaplan-Meier survival curve chart showing probability (%) on the y-axis and time in months on the x-axis. Two lines represent different groups labeled TCF (solid line) and CF (dashed line), depicting survival probability over a 24-month period.*
FDA Label Image

Figure 7: Gastric Cancer Study (tax325) Survival K-m Curve (Image 10)

Figure 7: Gastric Cancer Study (tax325) Survival K-m Curve (Image 10)
A survival probability curve graph depicting survival time in months on the x-axis and survival probability percentage on the y-axis. Two lines represent different groups labeled TPF and PF, showing their respective survival probabilities over time up to 72 months.*
FDA Label Image

Figure 8: Tax323 Progression-free Survival K-m Curve (Image 11)

Figure 8: Tax323 Progression-free Survival K-m Curve (Image 11)
A survival probability plot showing patient survival over time in months, comparing two groups labeled TPF (n=255) and PF (n=246). The y-axis represents survival probability (%) from 0 to 100%, and the x-axis shows survival time up to 72 months. A table below the chart indicates the number of patients at risk at various time points for each group.*
FDA Label Image

Figure 9: Tax323 Overall Survival K-m Curve (Image 12)

Figure 9: Tax323 Overall Survival K-m Curve (Image 12)
Packaging label for Docetaxel Injection, USP 160 mg/16 mL (10 mg/mL) by Mylan Institutional LLC. The label includes cautionary statements about cytotoxicity and concentration checks, directions for intravenous use only, and storage instructions. It indicates the product is sterile, available as a multiple-dose vial, and manufactured in India.*
FDA Label Image

Figure 10: Tax324 Overall Survival K-m Curve (Image 13)

Figure 10: Tax324 Overall Survival K-m Curve (Image 13)
A survival probability line graph comparing two groups labeled TPF (n=255) and PF (n=246) over a survival time in months, ranging from 0 to 72. The vertical axis shows survival probability (%) from 0 to 100. The chart includes a table below indicating the number of patients at risk at various time points for both groups.*
FDA Label Image

Docetaxel Injection 20 mg/2 mL Carton Label (Image 01)

Docetaxel Injection 20 mg/2 mL Carton Label (Image 01)
Packaging label for Docetaxel Injection, USP 20 mg/2 mL (10 mg/mL) by Mylan Institutional LLC. The label includes warnings about cytotoxicity, instructions to discard unused portions, and storage conditions. It states that the product is a sterile, single-dose vial for intravenous use, ready to add to infusion solution. The label notes distribution by Mylan Institutional LLC and manufacturing in India by Viatris.*
FDA Label Image

Docetaxel Injection 80 mg/8 mL Carton Label (Image 02)

Docetaxel Injection 80 mg/8 mL Carton Label (Image 02)
Label for Docetaxel Injection, USP 80 mg/8 mL (10 mg/mL) solution for intravenous use by Mylan Institutional LLC. The label highlights it is a sterile, cytotoxic agent, ready to add to infusion solution, packaged in an 8 mL multiple-dose vial. Storage and usage warnings are included alongside barcodes and manufacturer details.*
FDA Label Image

Docetaxel Injection 160 mg/16 mL Carton Label (Image 03)

Docetaxel Injection 160 mg/16 mL Carton Label (Image 03)
Label for Docetaxel Injection, USP, 160 mg/16 mL (10 mg/mL) solution for intravenous use, manufactured by Mylan Institutional LLC, a Viatris company. The label includes dosage strength, usage warnings including cytotoxic agent caution, storage instructions, NDC 67457-533-16, and barcode. It specifies the product is sterile, Rx only, in a 16 mL multiple-dose vial format.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.